Advertisement
Jamie Paterson, a British national, can look back at 20 years ofexperience in the pharmaceutical industry. Prior to joining Viroblock he wasChief Commercial Officer at Neurim Pharmaceuticals. During his 18 years atProcter & Gamble he held several positions with increasing responsibilityincluding Marketing Manager Italy and Commercial Director Spain. His finalposition at P&G was European Director of Strategic Planning and New BusinessDevelopment - Rx & OTC. Jamie holds a PhD in Biochemistry from ImperialCollege, University of London.
Advertisement
"I welcome Jamie as our new CEO and I am pleased to concentrate myactivities to further demonstrate scientifically the potential of ourtechnology in several viral indications" said Thierry Pelet who is one theco-founders of the company. Thierry will assume the position of Chief ScienceOfficer (CSO).
Viroblock further announced that it has completed its second round ofequity funding. The Series B financing round was led by Fongit Seed InvestSA. Peter Pfister, Initiative Capital Romandie SA (managed by DEFI Gestion)and BlueOcean Ventures acted as co-investors.
"With Jamie and Thierry we have a strong leadership team with provenbusiness skills and accomplished scientific know-how. This team equipped withthe additional funding can now start developing our first anti-viralproducts, which will bring the company to the next level, said Peter Pfister,Chairman of the Board.
About Viroblock
Viroblock is dedicated to developing and commercializing a new generationof anti-viral products with a novel mechanism of action against envelopedviruses. Enveloped viruses represent more than 60% of all existing virusesand include major human pathogens such as human and avian influenzas, thehepatitis B and C viruses and the AIDS virus.
Viroblock's unique proprietary products and technologies open verypromising opportunities in a number of prophylactic and therapeuticapplications.
Viroblock was founded in October 2005 by the late Donald Wallach, ascientist and academic with past tenure at the Harvard Medical School andTufts University, and a pioneer in the research of liposome systems.For more information: Thierry Pelet +41-22-884-8344 [email protected]
SOURCE Viroblock SA
